IDEAS home Printed from https://ideas.repec.org/a/ids/ijbenv/v1y2006i2p253-264.html
   My bibliography  Save this article

Innovation and firm size in the pharmaceutical industry

Author

Listed:
  • Roxana Bobulescu
  • Celine Soulas

Abstract

The paper explains the main features of the relationship between firm size and innovativeness in the pharmaceutical industry. As the biotechnological paradigm is progressively replacing the chemical one, the biotech start-ups are the principal engine of R&D activity. They discover new molecules and impulse drug innovation. Still, big pharmaceutical companies (big pharmas) have some advantages, such as benefiting from higher funds to support development of new drugs, scale and scope economies in R&D. Partnerships between small and big firms are developed on a win-win basis. Consequently, the size of the firm is a moving target. Innovation is to be linked with industrial, technological networks. Small firms are cooperating and so increasing returns to scale may appear at the level of the research networks, strategic alliances or bio-clusters. Industrial policies stimulating innovation as a competitive edge should then concentrate on creating strong incentives for small firms to cooperate.

Suggested Citation

  • Roxana Bobulescu & Celine Soulas, 2006. "Innovation and firm size in the pharmaceutical industry," International Journal of Business Environment, Inderscience Enterprises Ltd, vol. 1(2), pages 253-264.
    • Handle: RePEc:ids:ijbenv:v:1:y:2006:i:2:p:253-264
    as

    Download full text from publisher

    File URL: http://www.inderscience.com/link.php?id=10687
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Carbonari, Lorenzo, 2012. "Quasi-fixed inputs in the Italian manufacturing: The case of the pharmaceutical industry," Applied Econometrics, Russian Presidential Academy of National Economy and Public Administration (RANEPA), vol. 25(1), pages 51-69.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ids:ijbenv:v:1:y:2006:i:2:p:253-264. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sarah Parker (email available below). General contact details of provider: http://www.inderscience.com/browse/index.php?journalID=69 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.